Flt3/MerTK Inhibitor MRX-2843: clinical trials recruiting now

Fewer than 3 recruiting trials found.

Phase breakdown

Conditions being studied

Recruiting trials involving Flt3/MerTK Inhibitor MRX-2843

• MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
  NCT04762199 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many recruiting trials involve Flt3/MerTK Inhibitor MRX-2843?

1 recruiting trial across 6 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.